CV Outcomes in Diabetes

Risk reduction with antihyperglycaemic therapies


Cardiovascular (CV) disease remains the leading cause of morbidity and mortality in patients with type 2 diabetes (T2D).


The opportunity for CV disease prevention in patients with T2D has recently expanded with antihyperglycaemic agents demonstrating significant reductions in the risk of major adverse cardiovascular events (MACE). Although the exact mechanisms of CV benefit remain uncertain, they appear to be unrelated to the direct glucose-lowering effects. These agents have triggered a shift beyond glucose control, to a broader strategy of comprehensive CV risk reduction.


CV specialists are well-positioned to play a key role in managing patients with T2D, including screening, aggressively treating CV risk factors, and incorporating the use of antihyperglycaemic agents into routine practice.

Close X
Other videos you might like

Section Advisor

Professor Mikhail N Kosiborod

Saint Luke's America Heart Institute, Kansas City, MO, US

The Radcliffe diabetes and CVD risk program is supported by an educational grant from Novo Nordisk.

Recent Videos

Video Series

e-SPACE CRM 2022

Andrew JS Coats, Stefan Anker,


EMPEROR-Preserved: Empagliflozin, Health Status, & QoL in Patients With HFp

Javed Butler,


ESC 2021 Discussion: The FIGARO-DKD Trial

Bertram Pitt, Harriette Van Spall,


ESC 2021 Discussion: The EMPEROR-Preserved Trial

Stefan Anker, Harriette Van Spall,

Video Series

SGLT2i Updates 2021

Stefan Anker, Shelley Zieroth, Andrew JS Coats, et al


ACC 21: Benefits of SGLT1/2 Inhibition Across the Full Spectrum of EF

Deepak L Bhatt, Harriette Van Spall,